secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2026-05-12T12:00:17+00:00
Accession:  0001193125-26-218225
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma Q1 net loss $18M; rezatapopt NDA for ovarian cancer targeted for Q1 2027
--------------------------------------------------------------------------------

- Cash and securities $93.5M at March 31, 2026; net cash used in operations $19.7M for Q1.
- Net loss $18M for Q1 2026 vs $17.4M in Q1 2025; R&D expenses decreased to $15.3M.
- Confirmed ORR 44% (32/72) for rezatapopt in platinum-resistant/refractory TP53 Y220C ovarian cancer from SGO April 2026.
- FDA granted Orphan Drug Designation for rezatapopt in TP53 Y220C positive ovarian cancer.
- Phase 1 results published in NEJM; NDA submission planned in Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/0001193125-26-218225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/pmvp-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-218225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer